Enfusion (NYSE:ENFN) Shares Gap Down to $8.65

Enfusion, Inc. (NYSE:ENFN) gapped down before the market opened on Tuesday . The stock had previously closed at $8.65, but opened at $8.36. Enfusion shares last traded at $8.68, with a volume of 54,531 shares trading hands.

Wall Street Analyst Weigh In

Separately, Morgan Stanley began coverage on shares of Enfusion in a research note on Friday, May 10th. They set an “overweight” rating and a $11.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Enfusion presently has an average rating of “Hold” and an average target price of $9.33.

Enfusion Stock Performance

The firm’s 50 day moving average price is $8.87 and its two-hundred day moving average price is $8.98. The firm has a market cap of $1.04 billion, a PE ratio of 278.67, a PEG ratio of 2.15 and a beta of 0.92.

Enfusion (NYSE:ENFN) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.05). Enfusion had a net margin of 1.40% and a return on equity of 6.60%. The firm had revenue of $48.05 million during the quarter, compared to analysts’ expectations of $47.67 million. During the same period last year, the company earned $0.04 EPS. On average, analysts forecast that Enfusion, Inc. will post 0.09 earnings per share for the current year.

Insider Transactions at Enfusion

In other news, Director Deirdre Somers sold 4,629 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $8.40, for a total value of $38,883.60. Following the transaction, the director now directly owns 43,312 shares in the company, valued at approximately $363,820.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Enfusion news, insider Bronwen Bastone sold 10,539 shares of the stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $8.17, for a total transaction of $86,103.63. Following the sale, the insider now directly owns 217,154 shares in the company, valued at approximately $1,774,148.18. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Deirdre Somers sold 4,629 shares of the stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $8.40, for a total transaction of $38,883.60. Following the sale, the director now owns 43,312 shares in the company, valued at $363,820.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,318 shares of company stock worth $296,688. 36.44% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enfusion

Hedge funds have recently added to or reduced their stakes in the business. Brown Capital Management LLC raised its holdings in shares of Enfusion by 6.5% in the 4th quarter. Brown Capital Management LLC now owns 11,817,661 shares of the company’s stock valued at $114,631,000 after purchasing an additional 724,502 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Enfusion by 17.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,487,815 shares of the company’s stock valued at $31,286,000 after purchasing an additional 512,479 shares in the last quarter. Scalar Gauge Management LLC acquired a new stake in shares of Enfusion in the 4th quarter valued at $1,993,000. Wasatch Advisors LP raised its holdings in shares of Enfusion by 34.2% in the 1st quarter. Wasatch Advisors LP now owns 792,083 shares of the company’s stock valued at $7,327,000 after purchasing an additional 201,771 shares in the last quarter. Finally, Principal Financial Group Inc. acquired a new stake in shares of Enfusion in the 1st quarter valued at $452,000. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.